跳至主要内容
临床试验/NCT00114205
NCT00114205已完成1 期

Phase I Trial of Intrapleural Docetaxel Administered Via an Implantable Catheter in Subjects With a Malignant Pleural Effusion

University of Virginia2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2003年7月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
24
试验地点
2
主要终点
Maximum tolerated dose by adverse event evaluation 1 month after treatment

研究概览

简要总结

RATIONALE: Giving drugs, such as docetaxel, directly into the pleura after surgery to drain the pleural effusion may help keep fluid from building up again.

PURPOSE: This phase I trial is studying the side effects, best way to give, and best dose of intrapleural docetaxel given after surgery in patients with malignant pleural effusion.

详细描述

OBJECTIVES:

Primary

  • Determine the maximum tolerated dose of intrapleural docetaxel in patients with malignant pleural effusion.

Secondary

  • Determine the toxicity profile of this drug in these patients.
  • Determine the pharmacokinetics of this drug in plasma and pleural fluid from these patients.
  • Determine the response in patients treated with this drug.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Maximum tolerated dose by adverse event evaluation 1 month after treatment

次要结局

  • Pharmacokinetics by serum and pleural fluid analyses through 1 month
  • Clinical response by chest x-ray response and survival

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验